News Quantified

VCYT – veracyte, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Veracyte Names Kevin Haas as Chief Development and Technology Officer [Yahoo! Finance]

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte (VCYT) was downgraded by Zacks Research from "strong-buy" to "hold".

Veracyte (VCYT) had its "underweight" rating reaffirmed by Morgan Stanley.

Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook [Yahoo! Finance]

8.4%

BEAT

27.5%

BEAT

15.5%

BEAT

1.2%

BEAT

Form 8-K VERACYTE, INC. For: Mar 13

Form 4 VERACYTE, INC. For: Mar 06 Filed by: Leite John

Form 4 VERACYTE, INC. For: Mar 06 Filed by: Chambers Rebecca

Form 4 VERACYTE, INC. For: Mar 06 Filed by: Wygant Jonathan

Form 4 VERACYTE, INC. For: Mar 06 Filed by: Stapley Marc

Top News Gainers

3/23 Form 4 VERACYTE, INC. For: Mar 20 Filed by: Anderson Bonnie H 16.7%

3/25 Form SEC STAFF LETTER VERACYTE, INC. 15.6%

2/29 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%

12/4 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 7.9%

4/24 Form DEFA14A VERACYTE, INC. 7.9%

6/27 Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019 7.5%

8/12 Form 4 VERACYTE, INC. For: Aug 09 Filed by: JONES EVAN/ FA 6.7%

10/26 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.5%

4/7 Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations 6.3%

10/19 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.1%

Top News Decliners

4/1 Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients -16.6%

3/11 Form 4 VERACYTE, INC. For: Mar 10 Filed by: Anderson Bonnie H -16.1%

10/22 Veracyte Announces Third Quarter 2019 Financial Results and Business Progress -15.7%

8/13 Form 4 VERACYTE, INC. For: Aug 12 Filed by: Anderson Bonnie H -8.2%

2/21 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.1%

10/24 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -7.3%

9/3 Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer -7.1%

8/1 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -6.8%

7/30 Form 10-Q VERACYTE, INC. For: Jun 30 -6.7%

4/14 Form 8-K VERACYTE, INC. For: Apr 13 -6.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day